Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445877 + FOLFOX6 +/- Bevacizumab in First-Line MSS Metastatic Colorectal Cancer
NCT07500298Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2026
- Primary completion
- Dec 2030
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of SAR445877 in colorectal cancer (CRC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started May 2026; status: recruiting.
02
Drugs
SAR445877
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07500298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07500298.